A large-scale genome study uncovered IL31 as a key genetic contributor to prurigo nodularis, linking it to immune-regulatory ...

Prurigo nodularis (PN) is an inflammatory skin condition marked by firm, itchy, often painful bumps (nodules) on the skin. Read on for more on causes and treatments.

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

Prurigo nodularis is an inflammatory skin condition that causes the development of intensely itchy skin and bumps or lumps (nodules) on the legs, arms, upper back, or abdomen. This article ...

NEW ORLEANS — Symptoms of prurigo nodularis were significantly improved after 16 weeks of monotherapy with nemolizumab, according to a presenter at the American Academy of Dermatology Annual ...

Prurigo nodularis (PN) causes bumps (nodules) on the skin that can range in size from 0.5–2 centimeters in diameter. The number of nodules can vary from 2–200.

By week 12, itch and pain scores decreased 78.3% and 53.7% in the prurigo nodular and chronic pruritus of unknown origins groups, respectively. No serious adverse events were reported.

The designation was based on data from a phase 2 study that evaluated the safety and efficacy of nemolizumab in adults with moderate-to-severe prurigo nodularis (N=70).

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...

Chronic pruritus, which is defined as itch persisting for more than 6 weeks, 1 is common. It may involve the entire skin (generalized pruritus) or only particular areas, such as the scalp, upper ...